Some conditions continue to be more frequently diagnosed even two years later
Two years after the acute phase of infection, COVID-19 continues to leave its mark on the human nervous system — a large Oxford-led study of 1.25 million patient records reveals that while depression and anxiety fade within months, the shadows of dementia, seizures, and cognitive impairment linger far longer, particularly among the elderly and, to a lesser extent, children. Published in The Lancet Psychiatry, the findings remind us that a pandemic's true toll is rarely settled when the fever breaks, but unfolds quietly across the years that follow.
- A study of over 1.25 million patients confirms that COVID-19 survivors face neurological risks — dementia, brain fog, seizures — that persist for at least two years after infection, far outlasting the virus itself.
- The reassuring news is narrow: depression and anxiety spike briefly after COVID-19 but normalize within two months, matching outcomes seen in patients who had other respiratory illnesses.
- The troubling news runs deeper — adults over 65 face sustained elevated risks of dementia and psychotic disorders, working-age adults battle lingering cognitive deficits, and even children show higher rates of seizures two years on.
- Different variants compounded the picture unevenly, with Delta driving sharply higher short-term risks of anxiety, strokes, and seizures, while Omicron followed a similar pattern.
- Health systems now face a slow-moving second crisis: a sustained wave of neurological diagnoses expected to arrive years after the pandemic's visible peak, with researchers still lacking answers on why COVID-19 causes these effects or how to prevent them.
A major observational study published in The Lancet Psychiatry has found that COVID-19 survivors continue to face elevated risks of serious neurological and psychiatric conditions — including dementia, seizures, and cognitive impairment — for up to two years after infection. Led by Professor Paul Harrison at the University of Oxford, the research compared 1.25 million COVID-19 patients against an equal number of people who had recovered from other respiratory illnesses, allowing scientists to isolate what is specific to COVID-19 rather than respiratory illness in general.
The findings are uneven in their comfort. Depression and anxiety, which surged in the weeks following infection, returned to baseline within roughly two months — a pattern no different from other respiratory illnesses. Children, meanwhile, showed lower overall rates of neurological complications than adults and were not at elevated risk for anxiety or depression. But the relief ends there. Working-age adults continued to show higher rates of brain fog and muscle disease two years out. Older adults faced persistent risks of dementia and psychotic disorders. And even children were not spared entirely, showing elevated rates of seizures and psychotic disorders across the follow-up period.
Different variants of the virus produced different risk profiles. Delta was associated with significantly higher short-term risks of anxiety, cognitive deficits, seizures, and ischemic strokes, while Omicron followed a broadly similar pattern. Statistician Max Taquet offered a measured reading of the data — encouraged by the transience of mood disorder risks, but sobered by the durability of conditions like dementia and seizures.
The study's implications reach beyond individual patients. Professor Harrison warned that health systems must prepare for a sustained influx of neurological diagnoses emerging years after the pandemic's acute phase. Critically, researchers still do not understand why COVID-19 produces these long-term effects — a knowledge gap that is likely to define medical research priorities for years to come.
Two years after infection, COVID-19 survivors still face a measurably higher risk of developing serious neurological and psychiatric conditions—dementia, seizures, cognitive impairment—compared to people who recovered from other respiratory infections. That's the finding of a large observational study published in The Lancet Psychiatry, which examined health records from over 1.25 million patients tracked across a two-year period following their initial infection.
The research team, led by Professor Paul Harrison at the University of Oxford, analyzed data on fourteen different neurological and psychiatric diagnoses drawn primarily from US electronic health records. They compared 1,284,437 people with confirmed COVID-19 infections—including 185,748 children, 856,588 working-age adults, and 242,101 people over 65—against an equal number of matched patients who had contracted other respiratory infections during the same timeframe. This control group allowed researchers to isolate what was specific to COVID-19 rather than attributing outcomes to respiratory illness in general.
The picture that emerges is uneven. Depression and anxiety, which spiked in the weeks immediately following COVID-19 infection, returned to baseline levels within roughly two months. By the end of the two-year follow-up, adults who had COVID-19 showed no greater incidence of these conditions than those who had other respiratory infections. That's the reassuring part. But other conditions told a different story. Adults aged 18 to 64 who had COVID-19 continued to show elevated risks of cognitive deficits—the "brain fog" many survivors report—and muscle disease even two years later. For people over 65, the risks persisted for dementia, brain fog, and psychotic disorders. Children, fortunately, showed lower overall rates of neurological and psychiatric complications than adults, and they were not at greater risk of anxiety or depression than children who had other respiratory infections. Yet even children demonstrated higher rates of seizures and psychotic disorders in the two years following COVID-19.
The researchers also examined whether different variants of the virus produced different long-term outcomes. The Alpha variant showed little change in neurological risk profiles compared to the pre-variant period. But the Delta variant was associated with significantly higher six-month risks of anxiety, cognitive deficits, seizures, and ischemic strokes, though interestingly with a lower risk of dementia diagnoses. The Omicron wave produced risk patterns similar to those seen during the Delta period.
Max Taquet, who led the statistical analyses, offered a measured assessment of the findings. The short-lived nature of depression and anxiety risks after COVID-19 is encouraging, he noted, as is the absence of increased psychiatric risk in children. But the persistence of conditions like dementia and seizures two years out remains troubling. The implications extend beyond individual patients to health systems themselves. As Professor Harrison emphasized, if new cases of neurological conditions linked to COVID-19 continue to emerge years after the acute pandemic phase has ended, hospitals and clinics will need to prepare for a sustained wave of diagnoses and treatment demands. The study also underscores a critical gap: researchers still do not fully understand why COVID-19 produces these long-term neurological effects, or what interventions might prevent or treat them. That knowledge gap will likely shape medical research agendas for years to come.
Citas Notables
New cases of neurological conditions linked to COVID-19 infection are likely to occur for a considerable time after the pandemic has subsided— Professor Paul Harrison, University of Oxford
It is worrying that some other conditions, such as dementia and seizures, continue to be more frequently diagnosed after COVID-19, even two years later— Max Taquet, University of Oxford
La Conversación del Hearth Otra perspectiva de la historia
So depression and anxiety go away within two months, but dementia and seizures don't. Why would the virus affect the brain differently depending on the condition?
That's the question the study can't answer yet. It's possible COVID damages the brain in ways that trigger immediate mood symptoms but also set off slower degenerative processes. Or maybe the virus itself lingers in neural tissue. We just don't know.
And older people are hit harder than younger people. Is that because their brains are more vulnerable, or because they were sicker when they had COVID?
The study doesn't separate those factors. It's likely both—older adults tend to have more severe acute infections, and their brains may be less resilient to injury. But that's speculation.
The Delta variant seemed to cause more seizures and strokes than Alpha. Does that mean Delta was actually more damaging to the nervous system?
Possibly. Or it could mean Delta infected more people overall, so more neurological cases appeared in absolute numbers. The study shows the pattern but not the mechanism.
What happens to someone diagnosed with dementia two years after COVID? Are they the same as other dementia patients?
The study doesn't follow that. It just counts diagnoses. A person with post-COVID dementia might progress differently, respond differently to treatment, or have a different underlying cause than someone with typical age-related dementia. That's another gap.
If health systems are preparing for years of neurological cases, what does that actually look like?
More neurology appointments, more cognitive screening, more long-term care beds. But also—and this is the harder part—more research funding to understand what's happening and how to prevent it. Right now we're mostly just counting the damage.